Pharmacokinetic-pharmacodynamic Modeling of Monoamine Oxidase A Inhibitory Activity and Behavior Improvement by Curcumin in the Mouse Forced Swimming Test

Chinese Journal of Natural Medicines

Volumn 9, Issue 4, 2011, Pages 293-304

  Xia, Xing ^a   Pan, Ying ^a   Ou Yang, Zhen ^b   Wang, Ju ^a   Pan, Lu Lin ^a   Zhu, Qin ^a   Huang, Jun Jian ^c   Kong, Ling Dong ^a  

^a NANJING UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

^c BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

Curcumin; Depression Behavior; Forced swimming test; Monoamine oxidase A; Pharmacokinetic pharmacodynamic modeling

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CURCUMIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CLIMBING; CONTROLLED STUDY; DEPRESSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; FORCED SWIMMING TEST; FRONTAL CORTEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; IMMOBILIZATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; REPEATED DRUG DOSE; SIMULATION; SINGLE DRUG DOSE;

EID: 79960402457     PISSN: 20956975     EISSN: 18755364     Source Type: Journal    
DOI: 10.1016/S1875-5364(11)60067-8     Document Type: Article

References (51)

1. Klimek V, Robertson G, Stockmeier CA, et al. Serotonin transporter and MAO-B levels in monoamine nuclei of the human brainstem are normal in major depression [J]. J Psychiat Res 2003, 37(5):387-397.
2. Knoll J The history of (-)deprenyl the first selective inhibitor of type B monoamine oxidase [J]. Vop Med Khim 1997, 43(6):482-493.
3. Wouters J Structural aspects of monoamine oxidase and its reversible inhibition [J]. Curr Med Chem 1998, 5(2):137-162.
4. Anderson MC, Hasan F, Mccrodden JM, et al. Monoamine-oxidase inhibitors and the cheese effect [J]. Neurochem Res 1993, 18(11):1145-1149.
5. Bonnet U Moclobemide: therapeutic use and clinical studies [J]. Cns Drug Rev 2003, 9(1):97-140.
6. Adli M, Pilhatsch M, Bauer M, et al. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression [J]. Pharmacopsychiatry 2008, 41(6):252-257.
7. Youdim MB, Collins GG, Sandler M, et al. Human brain monoamine oxidase: multiple forms and selective inhibitors [J]. Nature 1972, 236(5344):225-228.
8. Tunstall RG, Sharma RA, Perkins S, et al. Cyclooxygenase-2 expression and oxidative DNA adducts in murine intestinal adenomas: Modification by dietary curcumin and implications for clinical trials [J]. Eur J Cancer 2006, 42(3):415-421.
9. Hsu CH, Cheng AL Clinical studies with curcumin [J]. Adv Exp Med Biol 2007, 595:471-480.
10. Mazzio EA, Harris N, Soliman KFA Food constituents attenuate monoamine oxidase activity and peroxide levels in C6 astrocyte cells [J]. Planta Med 1998, 64(7):603-606.
11. Xu Y, Ku BS, Yao HY, et al. Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats [J]. Pharmacol Biochem Behav 2005, 82(1):200-206.
12. Xu Y, Ku BS, Tie L, et al. Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB [J]. Brain Res 2006, 1122(1):56-64.
13. Xu Y, Ku BS, Cui L, et al. Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats [J]. Brain Res 2007, 1162:9-18.
14. Xia X, Pan Y, Zhang WY, et al. Ethanolic extracts from Curcuma longa attenuates behavioral, immune, and neuroendocrine alterations in a rat chronic mild stress model [J]. Biol Pharm Bull 2006, 29(5):938-944.
15. Xia X, Cheng G, Pan Y, et al. Behavioral, neurochemical and neuroendocrine effects of the ethanolic extract from Curcuma longa L. in the mouse forced swimming test [J]. J Ethnopharmacol 2007, 110(2):356-363.
16. Kulkarni SK, Bhutani MK, Bishnoi M Antidepressant activity of curcumin: involvement of serotonin and dopamine system [J]. Psychopharmacology 2008, 201(3):435-442.
17. Wang R, Xu Y, Wu HL, et al. The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors [J]. Eur J Pharmacol 2008, 578(1):43-50.
18. Wang R, Li YB, Li YH, et al. Curcumin protects against glutamate excitotoxicity in rat cerebral cortical neurons by increasing brain-derived neurotrophic factor level and activating TrkB [J]. Brain Res 2008, 1210:84-91.
19. Bhutani WK, Bishnoi M, Kulkarni SK Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes [J]. Pharmacol Biochem Be 2009, 92(1):39-43.
20. Li YC, Wang FM, Pan Y, et al. Antidepressant-like effects of curcumin on serotonergic receptor-coupled AC-cAMP pathway in chronic unpredictable mild stress of rats [J]. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(3):435-449.
21. Porsolt RD, Lepichon M, Jalfre M Depression-new animal-model sensitive to antidepressant treatments [J]. Nature 1977, 266(5604):730-732.
22. Detke MJ, Rickels M, Lucki I Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants [J]. Psychopharmacology 1995, 121(1):66-72.
23. Lucki I The forced swimming test as a model for core and component behavioral effects of antidepressant drugs [J]. Behav Pharmacol 1997, 8(6-7):523-532.
24. Tanaka M, Telegdy G Antidepressant-like effects of the CRF family peptides, urocortin 1, urocortin 2 and urocortin 3 in a modified forced swimming test in mice [J]. Brain Res Bull 2008, 75(5):509-512.
25. Schurr A, Livne A Differential inhibition of mitochondrial monoamine oxidase from brain by hashish components [J]. Biochem Pharmacol 1976, 25(10):1201-1203.
26. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein Measurement with the Folin Phenol Reagent [J]. J Biol Chem 1951, 193(1):265-275.
27. Chen Y, Kong LD, Xia X, et al. Behavioral and biochemical studies of total furocoumarins from seeds of Psoralea corylifolia in the forced swimming test in mice [J]. J Ethnopharmacol 2005, 96(3):451-459.
28. Pak Y, Patek R, Mayersohn M Sensitive and rapid isocratic liquid chromatography method for the quantitation of curcumin in plasma [J]. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 796(2):339-346.
29. Hao K, Zhao XP, Liu XQ, et al. LC determination of curcumin in dog plasma for a pharmacokinetic study [J]. Chromatographia 2006, 64(9-10):531-535.
30. D'Argenio DZ, Shumitzky A ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software [M] 1997, 45-52. Biomedical Simulations Resource, Los Angeles.
31. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics - application to D-tubocurarine [J]. Clin Pharmacol Ther 1979, 25(3):358-371.
32. Branski P, Palucha A, Szewczyk B, et al. Antidepressant-like activity of 8-Br-cAMP, a PKA activator, in the forced swim test [J]. J Neural Transm 2008, 115(6):829-830.
33. Gersner R, Gordon-Kiwkowitz M, Zangen A Automated behavioral analysis of limbs' activity in the forced swim test [J]. J Neurosci Meth 2009, 180(1):82-86.
34. Ferigolo M, Barros HMT, Marquardt AR, et al. Comparison of behavioral effects of moclobemide and deprenyl during forced swimming [J]. Pharmacol Biochem Behav 1998, 60(2):431-437.
35. Reneric JP, Lucki I Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test [J]. Psychopharmacology 1998, 136(2):190-197.
36. Cryan JF, Lucki I Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine(2C) receptors [J]. J Pharmacol Exp Ther 2000, 295(3):1120-1126.
37. Lopez-Rubalcava C, Lucki I Strain differences in the behavioral effects of antidepressant drugs in the rat forced swimming test [J]. Neuropsychopharmacol 2000, 22(2):191-199.
38. Pan MH, Huang TM, Lin JK Biotransformation of curcumin through reduction and glucuronidation in mice [J]. Drug Metab Dispos 1999, 27(4):486-494.
39. Yang KY, Lin LC, Tseng TY, et al. Oral bioavailabilit of curcurnin in rat and the herbal analysis from Curcuma longa by LC-MS/MS [J]. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 853(1-2):183-189.
40. Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers [J]. Planta Med 1998, 64(4):353-356.
41. Ravindranath V, Chandrasekhara N Metabolism of curcumin-studies with [3H]curcumin [J]. Toxicology 1981, 22(4):337-344.
42. Perkins S, Verschoyle RD, Hill K, et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the Min/+ mouse, a model of familial adenomatous polyposis [J]. Cancer Epidem Biomar 2002, 11(6):535-540.
43. Yang FS, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo [J]. J Biol Chem 2005, 280(7):5892-5901.
44. Rajeswari A, Sabesan M Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice [J]. Inflammopharmacology 2008, 16(2):96-99.
45. Holder GM, Plummer JL, Ryan AJ The metabolism and excretion of curcumin (1, 7-bis-(4-hydroxy-3-methoxyphenyl)- 1, 6-heptadiene-3, 5-dione) in the rat [J]. Xenobiotica 1978, 8(12):761-768.
46. Asai A, Miyazawa T Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma [J]. Life Sci 2000, 67(23):2785-2793.
47. Liu A, Lou H, Zhao L, et al. Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin [J]. J Pharm Biomed Anal 2006, 40(3):720-727.
48. Sugiyama Y, Kawakishi S, Osawa T Involvement of the beta-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin [J]. Biochem Pharmacol 1996, 52(4):519-525.
49. Lin JK Molecular targets of curcumin [J]. Adv Exp Med Biol 2007, 595:227-243.
50. Mandel S, Amit T, Bar-Am O, et al. Iron dysregulation in Alzheimer's disease: Multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents [J]. Prog Neurobiol 2007, 82(6):348-360.
51. Goel A, Kunnumakkara AB, Aggarwal BB Curcumin as " Curecumin": From kitchen to clinic [J]. Biochem Pharmacol 2008, 75(4):787-809.